TY  - GEN
AB  - Potent  and  specific  kinase  inhibitors  have  revolutionized  the  treatment  of  kinase-driven  cancers  by  providing  targeted  inhibition  of  known  cancer  driving  kinases.    However,  disease  resistance  and  disease  persistence  have  prevented  targeted  kinase  therapy  from  being  curative.    Depending  upon  the  disease  state,  kinase  inhibitors  may  be  effective  for  many  years  or  only  a  few  months  before  secondary  resistance  develops.   Even  for  diseases  where  treatment  is  efficacious  for  many  years,  patients  must  be  treated continuously, as interruption of the therapy results in disease growth within a few  weeks or months.  The goal of this thesis work was to address both disease resistance  and  persistence  in  KIT-mutant  mast  cell  cancer  models  through  the  development  of  novel combination therapies.
AD  - Oregon Health and Science University
AU  - Macleod, Alison
DA  - 2013
DO  - 10.6083/M4FB5186
DO  - DOI
ED  - Heinrich, Michael
ED  - Advisor
ID  - 2730
KW  - Neoplasms
KW  - Mastocytosis
KW  - Proto-Oncogene Proteins c-kit
KW  - Drug Therapy, Combination
KW  - cancer
KW  - mast cell disease
L1  - https://digitalcollections.ohsu.edu/record/2730/files/3459_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/2730/files/3459_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/2730/files/3459_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/2730/files/3459_etd.pdf
N2  - Potent  and  specific  kinase  inhibitors  have  revolutionized  the  treatment  of  kinase-driven  cancers  by  providing  targeted  inhibition  of  known  cancer  driving  kinases.    However,  disease  resistance  and  disease  persistence  have  prevented  targeted  kinase  therapy  from  being  curative.    Depending  upon  the  disease  state,  kinase  inhibitors  may  be  effective  for  many  years  or  only  a  few  months  before  secondary  resistance  develops.   Even  for  diseases  where  treatment  is  efficacious  for  many  years,  patients  must  be  treated continuously, as interruption of the therapy results in disease growth within a few  weeks or months.  The goal of this thesis work was to address both disease resistance  and  persistence  in  KIT-mutant  mast  cell  cancer  models  through  the  development  of  novel combination therapies.
PB  - Oregon Health and Science University
PY  - 2013
T1  - Combination treatment to target KIT mutant cells
TI  - Combination treatment to target KIT mutant cells
UR  - https://digitalcollections.ohsu.edu/record/2730/files/3459_etd.pdf
Y1  - 2013
ER  -